Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Healthcare and Community Service Utilisation in Older Survivors of Critical Illness

NCT07870343 · tracked via the Priya Life Science Australia tracker
Phase
Observational
Started
2026-11-01
Last updated
2026-10-13

Condition(s) studied

Critical Illness

Study summary

This prospective observational study will describe healthcare and community service utilisation among older adults who survive critical illness and return to the community following hospital discharge. Participants will be adults aged 65 years or older who have been admitted to an intensive care unit (ICU) for at least 48 hours and survive to hospital discharge. Healthcare and community service use will be assessed during the first 90 days after hospital discharge using weekly telephone surveys, participant-completed health diaries, and review of participants' electronic medical records. The study will describe use of general practitioner, medical specialist, allied health, nursing and community services, as well as self-reported needs and barriers to accessing these services, emergency department presentations, hospital readmissions and mortality. Findings will help inform the development of future models of follow-up care for older survivors of critical illness.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Was admitted to ICU for ≥48 hours 2. Is aged ≥65 years old 3. Is returning to community-dwelling Exclusion Criteria: 1. Is planned for discharge against medical advice 2. Is planned for discharge to another inpatient facility 3. Is not expected to reside in Australia for 90 days following hospital discharge 4. Is not expected to survive for 90 days following hospital discharge 5. Is not able to participate in the study procedures 6. Is not able to read and speak English 7. Is not eligible for Medicare 8. Has declined or is unable to provide consent.

Primary outcome measure(s)

  • Utilisation of General Practitioner (GP) services — 90 days following hospital discharge

Trial sites (1)

FacilityCityRegionStatus
The Alfred Hospital Melbourne Victoria
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07870343 on ClinicalTrials.gov ↗ ← All trials in Australia